229 related articles for article (PubMed ID: 32817393)
1. Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery.
Zheng Z; Zhang J; Jiang J; He Y; Zhang W; Mo X; Kang X; Xu Q; Wang B; Huang Y
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817393
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting biomimetic delivery for anti-glioma activity
Zhao P; Wang Y; Kang X; Wu A; Yin W; Tang Y; Wang J; Zhang M; Duan Y; Huang Y
Chem Sci; 2018 Mar; 9(10):2674-2689. PubMed ID: 29732051
[TBL] [Abstract][Full Text] [Related]
3. Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery.
Chen B; Gao A; Tu B; Wang Y; Yu X; Wang Y; Xiu Y; Wang B; Wan Y; Huang Y
Biomaterials; 2020 Oct; 255():120187. PubMed ID: 32590192
[TBL] [Abstract][Full Text] [Related]
4. The influx/efflux mechanisms of d-peptide ligand of nAChRs across the blood-brain barrier and its therapeutic value in treating glioma.
Han B; Xie W; Zhang Y; Zhou S; Yang J; Wang R; Sun Y; Wang X; Xu J; Chen D; Wang Y; Lu J; Ning F; Shen F; Liu M; Cai H; Xin H; Lu W; Zhang X
J Control Release; 2020 Nov; 327():384-396. PubMed ID: 32791079
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1.
Wang H; Tang Y; Fang Y; Zhang M; Wang H; He Z; Wang B; Xu Q; Huang Y
Nano Lett; 2019 May; 19(5):2935-2944. PubMed ID: 30950276
[TBL] [Abstract][Full Text] [Related]
6. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment.
Tu B; He Y; Chen B; Wang Y; Gao Y; Shi M; Liu T; Asrorov AM; Huang Y
Biomater Sci; 2020 Dec; 8(24):7166-7176. PubMed ID: 33169732
[TBL] [Abstract][Full Text] [Related]
7. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
8. Liposome-Based Systemic Glioma-Targeted Drug Delivery Enabled by All-d Peptides.
Ying M; Zhan C; Wang S; Yao B; Hu X; Song X; Zhang M; Wei X; Xiong Y; Lu W
ACS Appl Mater Interfaces; 2016 Nov; 8(44):29977-29985. PubMed ID: 27797175
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy.
Zhu Y; Liang J; Gao C; Wang A; Xia J; Hong C; Zhong Z; Zuo Z; Kim J; Ren H; Li S; Wang Q; Zhang F; Wang J
J Control Release; 2021 Feb; 330():641-657. PubMed ID: 33359582
[TBL] [Abstract][Full Text] [Related]
10. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
[No Abstract] [Full Text] [Related]
11. CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin.
Jang Y; Cho YS; Kim A; Zhou X; Kim Y; Wan Z; Moon JJ; Park H
ACS Appl Mater Interfaces; 2024 Apr; 16(14):17129-17144. PubMed ID: 38533538
[TBL] [Abstract][Full Text] [Related]
12. Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide.
Mo X; Zheng Z; He Y; Zhong H; Kang X; Shi M; Liu T; Jiao Z; Huang Y
J Control Release; 2018 Oct; 287():12-23. PubMed ID: 30096402
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
14. Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages.
Ye J; Yang Y; Dong W; Gao Y; Meng Y; Wang H; Li L; Jin J; Ji M; Xia X; Chen X; Jin Y; Liu Y
Int J Nanomedicine; 2019; 14():3203-3220. PubMed ID: 31118632
[No Abstract] [Full Text] [Related]
15. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
16. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting.
Liu Y; Ran R; Chen J; Kuang Q; Tang J; Mei L; Zhang Q; Gao H; Zhang Z; He Q
Biomaterials; 2014 Jun; 35(17):4835-47. PubMed ID: 24651033
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
19. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
20. Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment.
Piperi C; Papavassiliou KA; Papavassiliou AG
Cells; 2019 Nov; 8(11):. PubMed ID: 31698775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
